StemCell Therapy

Text Size:A- A+

New Delhi: Over 20 research institutes are working overnight to develop vaccines for the treatment of the highly infectious novel coronavirus, said a top government official.

The National Institute of Virology (NIV), Pune, and the Indian Council of Medical Research (ICMR) are among these research institutes.

According to Renu Swarup, Secretary, Department of Biotechnology (DBT), which functions under the Ministry of Science and Technology, the government has received over 7,000 tech-based proposals from private companies and individuals across the country to fight Covid-19.

In an interview to ThePrint, Swarup further said the government is dealing with several aspects from scaling up production of low-cost Covid-19 testing kits and ventilators to expediting research for the development of vaccine to fight the novel coronavirus.

We are working on several aspects right now. First is scaling up the manufacturing capacity of those start-ups and incubators, who have made low-cost testing kits and ventilators. They got early approval from the NIV and ICMR also. Eight to nine companies are in the process to get approval for their kits and ventilators, said Swarup.

We are also supporting those companies who got approval for commercial production of testing kits and ventilators. Besides, all IIT-incubators have been asked to focus on research and development of portable ventilators, on genome sequencing and on isolation of the strain of the novel coronavirus from blood samples, she added.

Also read: How do you test for coronavirus? All you want to know about testing kits, process, results

Swarup said IIT-Kanpur and IIT-Roorkee incubation centers are working on making portable ventilators.

We are also supporting three indigenous companies in scaling up their manufacturing capacity of providing ventilators at a fast pace. A Mysuru-based firm is also ramping up its capacity to make more ventilators. It is working with the NITI Aayog, DBT, DRDO (Defence Research and Development Organisation) to manufacture more ventilators, she said.

The DBT is also supporting private companies to procure local components to manufacture ventilators because there is a problem in sourcing them from outside now (in the wake of the lockdown), she added.

An ICMR official told ThePrint ventilators and testing kits are extremely essential if the outbreak reaches the third stage.

India, with less than 1 lakh intensive care units and a bed ratio of 1:1,000, will be at risk if outbreak reaches the third stage. The unique nature of the disease requires 3-4 week of recovery and 21-day ventilator support, said the official.

Ventilators are the next level weapon after a test kit, which is required in sufficient numbers in case of a mass outbreak, he added.

Swarup said the coronavirus research consortium, which has experts from the ICMR, DBT, NIV, are working to develop a vaccine for Covid-19.

We are researching new molecules for treatment. We are researching repurposed drugs to treat patients. More than 45 drugs have been identified that may be effective and research is going on. Several DBT institutions are working to see which formulations can work effectively against Covid-19, she said.

We are also sharing our research with international consortium, which are working on vaccine development. But in any case, it will take time. They are at the animal trial stage and it will reach stage three of human trail not before year end, she added.

Over 7,000 technological solutions were received by the government as part of its COVID-19 Solution Challenge.

Under the initiative, individuals and companies can submit their tech-based ideas for strengthening the fight against coronavirus.

Several tech giants such as Microsoft, Intel, Amazon, Google have pitched ideas for making artificial intelligence-based solutions to detect suspected cases of coronavirus using the ICMR data. Ideas to manufacture low-cost ventilators, low-cost test kits and herbal sanitisers also came, the DBT secretary told ThePrint.

Swarup said all these ideas are being vetted.

A committee headed by K. VijayRaghavan, principal scientific adviser to the government, is evaluating the ideas and the DBT will support the selected research proposal, she added.

The DBT has also invited proposals from companies working in the field of research and development to manufacture ventilators, testing kits, for which it will provide the required funding, the DBT secretary added.

Also read: By failing to scale up testing coronavirus, India may have lost crucial time

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

View original post here:
20 Indian institutes working to find Covid-19 vaccine, IITs focused on portable ventilators - ThePrint

Item 8.01 Other Events.

Green Vision Biotechnology Corp. (the "Company") hereby announces that it isrelying the order of the Securities and Exchange Commission, Release No.34-88318, dated March 4, 2020 for the extension of the filing deadline of itsAnnual Report on Form 10-K, for the year ended December 31, 2019. There was anoutbreak of Coronavirus in China at the end of January, 2020. In order to avoidthe risk of the virus spreading, the Chinese government required enterprises todelay the resumption of work and production, this included City lockdown, travelsuspension, operation suspension, 14-days quarantine, and the work from home.The Company has major operation in Jinzhong, Shanxi and abided by the governmentrule to suspend operation since late January 2020. This has hindered theprogress of performing audit procedures so as to express an appropriate auditopinion for the audit of the Company. Because of the government order to suspendoperation, the Company's accounting staff could not access to the physicalrecords of the Company which cause a delay in providing the relevant informationto the Company's independent public accountant so as to perform the requiredaudit procedures.

The delay to provide responses to auditor inquiries also effected thehardworking of the Company's management because it took more time to collect theappropriate information, access and locate relevant documents, and re-arrangevarious resources. The aforementioned and the subsequent delays relating to thecompletion of audit procedures have caused the filing of the Form 10-K on orbefore April 15, 2020 to become impossible. The Company expects to file theannual report on Form 10-K on May 15, 2020.

Item 9.01 Financial Statements and Exhibits.

Edgar Online, source Glimpses

The rest is here:
GREEN VISION BIOTECHNOLOGY CORP. : Other Events, Financial Statements and Exhibits (form 8-K) - marketscreener.com

While biotech stocks are often too risky for many investors, with the coronavirus raging and the race for a vaccine in play, taking a look at some ETFs that contain biotech stocks that are making strides might not be such a bad idea.

With the COVID-19 pandemic raging, biotechs that are consistently profitable and that offer drugs that patients absolutely must have could be seen as relatively safe compared to many other stocks on the market. For investors looking to stay in the market and diversify portfolios, here are two biotech ETFs that could be worth diversifying into during the coronavirus crisis.

With biotech companies like Gilead Sciences, which has been in the news a lot recently for the antiviral drug remdesivir, which appears to be the most promising treatment for COVID-19, IBB is a place for biotech investors to consider. Gilead is conducting late-stage studies of the drug and could report initial results as early as April. Gilead also has adividend yield currently stands at nearly 4%. The company has even augmented its dividend by 58% over the last five years.

IBB seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

While the iShares Genomics Immunology and Healthcare ETF has no directly related coronavirus drug-making companies in its holdings, it does contain stocks like Exelixis, which makes drugs that are used to treat kidney, liver, and medullary thyroid cancer, which will continue to be important going forward. The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

For more market trends, visitETF Trends.

Visit link:
2 Biotechnology ETFs That Could Be Good For Diversification - ETF Trends

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. Well use ROE to examine Apex Biotechnology Corp. (TPE:1733), by way of a worked example.

Apex Biotechnology has a ROE of 6.7%, based on the last twelve months. That means that for every NT$1 worth of shareholders equity, it generated NT$0.07 in profit.

View our latest analysis for Apex Biotechnology

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) Shareholders Equity

Or for Apex Biotechnology:

6.7% = NT$113m NT$1.7b (Based on the trailing twelve months to December 2019.)

Most readers would understand what net profit is, but its worth explaining the concept of shareholders equity. It is the capital paid in by shareholders, plus any retained earnings. Shareholders equity can be calculated by subtracting the total liabilities of the company from the total assets of the company.

ROE measures a companys profitability against the profit it retains, and any outside investments. The return is the yearly profit. A higher profit will lead to a higher ROE. So, as a general rule, a high ROE is a good thing. That means ROE can be used to compare two businesses.

By comparing a companys ROE with its industry average, we can get a quick measure of how good it is. The limitation of this approach is that some companies are quite different from others, even within the same industry classification. If you look at the image below, you can see Apex Biotechnology has a lower ROE than the average (9.9%) in the Medical Equipment industry classification.

Unfortunately, thats sub-optimal. It is better when the ROE is above industry average, but a low one doesnt necessarily mean the business is overpriced. Nonetheless, it might be wise to check if insiders have been selling.

Companies usually need to invest money to grow their profits. That cash can come from issuing shares, retained earnings, or debt. In the first and second cases, the ROE will reflect this use of cash for investment in the business. In the latter case, the use of debt will improve the returns, but will not change the equity. Thus the use of debt can improve ROE, albeit along with extra risk in the case of stormy weather, metaphorically speaking.

Apex Biotechnology has a debt to equity ratio of 0.29, which is far from excessive. Although the ROE isnt overly impressive, the debt load is modest, suggesting the business has potential. Careful use of debt to boost returns is often very good for shareholders. However, it could reduce the companys ability to take advantage of future opportunities.

Return on equity is useful for comparing the quality of different businesses. Companies that can achieve high returns on equity without too much debt are generally of good quality. If two companies have the same ROE, then I would generally prefer the one with less debt.

Having said that, while ROE is a useful indicator of business quality, youll have to look at a whole range of factors to determine the right price to buy a stock. Profit growth rates, versus the expectations reflected in the price of the stock, are a particularly important to consider. So you might want to take a peek at this data-rich interactive graph of forecasts for the company.

Of course Apex Biotechnology may not be the best stock to buy. So you may wish to see this free collection of other companies that have high ROE and low debt.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the original post:
Should You Be Concerned About Apex Biotechnology Corp.s (TPE:1733) ROE? - Simply Wall St

FARMINGTON, Conn., March 20, 2020 /PRNewswire/ --ImStem Biotechnology, Inc. (Farmington CT), a biopharmaceutical company pioneering the development of human embryonic stem cell (ESC) derived mesenchymal stem cells (hES-MSC), through a proprietary method using a trophoblast intermediate stage (hence also known as T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS). IMS001 is an investigational, allogeneic cell product to be administered intravenously to patients suffering from MS. We believe this is the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA. The company plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.

"As an inventor of our proprietary technology, we look forward to building a company whose foundation lies in our science based upon years of pioneering research," said Dr. Xiaofang Wang, Chief Technology Officer of ImStem Biotechnology.

About IMS001

IMS001 is an investigational, allogeneic, hES-MSC product derived from human embryonic stem cell line. IMS001 has demonstrated preclinical immunomodulatory and blood-brain-barrier (BBB) repair activities, which may lead to potential therapeutic benefits in a wide array of neurological, autoimmune, and rare orphan diseases with high unmet medical needs. These mechanistic properties may lead to therapeutic benefits in diseases such as MS, potentially reducing relapses, disability progression, and inducing disease arrest.

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The company's mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem biotechnology Inc. is a privately held company headquartered in Farmington, CT. For more information, visit http://www.imstem.com.

Media Contact:Investor Relations235411@email4pr.com860-281-7836

View original content:http://www.prnewswire.com/news-releases/imstem-biotechnology-announces-fda-has-lifted-the-clinical-hold-on-the-investigational-new-drug-application-for-ims001-for-the-treatment-of-multiple-sclerosis-301027733.html

SOURCE ImStem Biotechnology, Inc.

Excerpt from:
ImStem Biotechnology Announces FDA has Lifted the Clinical Hold on the Investigational New Drug Application for IMS001 for the Treatment of Multiple...

The "Global Next-Generation Biomanufacturing Market: Focus on Workflow, Product Type, Medical Applications, End Users, 5 Regional Data, 19 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

The Global Next-Generation Biomanufacturing Market Report projects the market to grow at a significant CAGR of 10% during the forecast period, 2019-2029.

The rapid maturation of the biopharmaceutical sector denotes the increasing importance of biomanufacturing as the most basic procedure for the development and manufacture of biologic-based products. With increasing commercialization of biopharmaceuticals and the addition of more products in the development pipeline, biopharmaceutical companies are looking forward to adopting novel biomanufacturing strategies with an increased focus on balancing innovation in process design, performance, and efficiency with speed and cost.

The need for advanced biomanufacturing practices in order to meet the demand of the growing patient population has paved the way for the development of next-generation biomanufacturing products. Next-generation biomanufacturing products are designed to provide seamless services that are superior in terms of both quality and efficiency as compared to first-generation products. Increased funding from private investors and the government for the development of next-generation biomanufacturing facilities promoting rapid technological advancement in biomanufacturing products is one of the most prominent factors driving the growth of the next-generation biomanufacturing market.

One of the major trends of the next-generation biomanufacturing market is the shifting focus toward the adoption of single-use products, such as single-use bioreactors and single-use biocontainers. This is mainly attributed to the huge number of benefits associated with single-use products, with regard to cost savings, reduced risk of product contamination, and increased flexibility in multi-product facilities.

With more companies entering the next-generation biomanufacturing market through product innovations, several novel next-generation biomanufacturing products are expected to come up, actively driving the growth of the market in the upcoming years.

Expert Quote

The leading contributors in the global next-generation biomanufacturing market predominantly prefer partnerships and alliances to sustain the market competition and strengthen their business position. Most of the market leaders are collaborating with technology-based startups to gain their expertise in technology.

Research Highlights

The leading contributors to the global next-generation biomanufacturing market predominantly prefer partnerships and alliances to sustain the market competition and strengthen their business position. Most of the market leaders are collaborating with technology-based startups to gain their expertise in technology.

Monoclonal antibody product segment with relatively high market approval rates is dominating the next-generation biomanufacturing market, by the medical application. Monoclonal antibodies segment was valued at $6.66 billion in 2018, contributing to 45% of the total market share in 2018.

In terms of end-users, commercial-stage end-user dominated the global next-generation biomanufacturing market and was valued at $11.39 billion in 2018. On the other hand, for both commercial-stage end-users and preclinical and development stage end users, biopharmaceutical companies were the major contributor of revenue, followed by CMOs/CDMOs.

Among the different regions, North America leads the global next-generation biomanufacturing market in 2018, with the U.S. being the major contributor to revenue. In 2018, North America contributed 35.40% of the total market share and the U.S. alone contributed to more than 95.4% of its market share.

This market intelligence report provides a multidimensional view of the global next-generation biomanufacturing market in terms of market size and growth potential. This research report aims at answering various aspects of the global next-generation biomanufacturing market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of market expansion.

Story continues

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities such as product launches, partnerships, and product approvals, among others. The research report provides a comprehensive analysis of the product sales, and manufacturers and trend analysis by segment and by region.

This report is a meticulous compilation of research on more than 10 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of the leading companies, market participants and vendors. The report also profiles 15 companies including several key players, such as Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Eppendorf AG, Sartorius AG, GEA Group Aktiengesellschaft, bbi-biotech GmbH, Esco Group of Companies, Pierre Gurin, Solaris Biotechnology Srl., PBS Biotech, Inc., ZETA GmbH, Applikon Biotechnology BV, Meissner Filtration Products, Inc., and Shanghai Bailun Biotechnology Co. Ltd.

Key Topics Covered

Executive Summary

1 Product Definition

2 Scope of the Work

2.1 Overview: Report Scope

2.2 Segmentation of the Global Next-Generation Biomanufacturing Market

2.3 Assumptions and Limitations

2.4 Key Questions Answered in the Report

2.5 Base Year and Forecast Period

3 Research Methodology

3.1 Overview: Report Methodology

4 Global Next-Generation Biomanufacturing Market Overview

4.1 Ever-Evolving Healthcare Scenario

4.2 Biomanufacturing: An Introduction

4.3 Upstream and Downstream Processing

4.4 Biopharmaceutical Market Growth Boosting Demand for Biomanufacturing

4.5 Key Technology Trends

4.6 The Future of Biomanufacturing: Next-Generation Biomanufacturing

4.7 Global Next-Generation Biomanufacturing Market Size

4.8 Market Dynamics

4.8.1 Impact Analysis of Market Dynamics

4.9 Assumptions and Limitations

5 Industry Insights

5.1 Overview

5.2 Regulatory Scenario

5.3 Patent Landscape

6 Competitive Landscape

6.1 Overview

6.2 Key Developments and Strategies

6.2.1 Partnerships and Alliances

6.2.2 Business Expansions

6.2.3 New Offerings

6.2.4 M & A Activities

6.2.5 Others

6.3 Market Share Analysis

7 Global Next-Generation Biomanufacturing Market (by Workflow and Product)

7.1 Overview

7.2 Upstream Biomanufacturing

7.2.1 Continuous Upstream Biomanufacturing Products

7.2.1.1 Bioreactors/Fermenters

7.2.1.2 Bags and Containers

7.2.1.3 Cell Culture Products

7.2.1.4 Filtration Systems

7.2.1.5 Mixing Systems

7.2.1.6 Sterilizers

7.2.1.7 Biosafety Cabinets

7.2.1.8 Incubators

7.2.1.9 Other Instruments and Accessories

7.2.2 Single-Use Upstream Biomanufacturing Products

7.2.2.1 Single-Use Bioreactors/Fermenters

7.2.2.2 Single-Use Bags and Containers

7.2.2.3 Single-Use Tubing and Connectors

7.2.2.4 Single-Use Mixing Systems

7.2.2.5 Single-Use Sensors and Probes

7.3 Downstream Processing

7.3.1 Downstream Biomanufacturing Products

7.3.1.1 Chromatography Systems

7.3.1.2 Filtration Systems

7.3.1.3 Membrane Adsorbers

7.3.1.4 Instruments and Accessories

7.3.1.5 Single-Use Equipment and Accessories

8 Global Next-Generation Biomanufacturing Market (by Medical Application)

8.1 Overview

8.2 Monoclonal Antibodies

8.3 Vaccines

8.4 Recombinant Proteins

8.5 Hormones

8.6 Others

9 Global Next-Generation Biomanufacturing Market (by End User)

9.1 Overview

9.2 Biopharmaceutical Companies

9.3 CMOs/CDMOs

9.4 Research Institutions

10 Global Next-Generation Biomanufacturing Market (by Region)

10.1 Overview

10.2 North America

10.3 Europe

10.4 Asia-Pacific

10.5 Latin America

10.6 Middle East & Africa

11 Company Profiles

11.1 Overview

11.2 Applikon Biotechnology B.V.

Go here to see the original:
Global Next-Generation Biomanufacturing Markets, 2019-2029: Focus on Workflow, Product Type, Medical Applications, End-users, and Competitive...

The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). Well look at Level Biotechnology Inc.s (GTSM:3118) P/E ratio and reflect on what it tells us about the companys share price. Level Biotechnology has a P/E ratio of 14.93, based on the last twelve months. That is equivalent to an earnings yield of about 6.7%.

See our latest analysis for Level Biotechnology

The formula for price to earnings is:

Price to Earnings Ratio = Share Price Earnings per Share (EPS)

Or for Level Biotechnology:

P/E of 14.93 = NT$21.800 NT$1.460 (Based on the year to December 2019.)

(Note: the above calculation results may not be precise due to rounding.)

The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings. That isnt necessarily good or bad, but a high P/E implies relatively high expectations of what a company can achieve in the future.

One good way to get a quick read on what market participants expect of a company is to look at its P/E ratio. As you can see below Level Biotechnology has a P/E ratio that is fairly close for the average for the healthcare industry, which is 14.4.

Level Biotechnologys P/E tells us that market participants think its prospects are roughly in line with its industry. If the company has better than average prospects, then the market might be underestimating it. Further research into factors such as insider buying and selling, could help you form your own view on whether that is likely.

Companies that shrink earnings per share quickly will rapidly decrease the E in the equation. That means even if the current P/E is low, it will increase over time if the share price stays flat. Then, a higher P/E might scare off shareholders, pushing the share price down.

Most would be impressed by Level Biotechnology earnings growth of 22% in the last year. In contrast, EPS has decreased by 9.2%, annually, over 5 years.

Its important to note that the P/E ratio considers the market capitalization, not the enterprise value. In other words, it does not consider any debt or cash that the company may have on the balance sheet. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

Level Biotechnology has net cash of NT$344m. This is fairly high at 46% of its market capitalization. That might mean balance sheet strength is important to the business, but should also help push the P/E a bit higher than it would otherwise be.

Level Biotechnologys P/E is 14.9 which is above average (12.9) in its market. With cash in the bank the company has plenty of growth options and it is already on the right track. So it is not surprising the market is probably extrapolating recent growth well into the future, reflected in the relatively high P/E ratio.

Investors should be looking to buy stocks that the market is wrong about. If the reality for a company is better than it expects, you can make money by buying and holding for the long term. We dont have analyst forecasts, but you might want to assess this data-rich visualization of earnings, revenue and cash flow.

Of course you might be able to find a better stock than Level Biotechnology. So you may wish to see this free collection of other companies that have grown earnings strongly.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

The rest is here:
Despite Its High P/E Ratio, Is Level Biotechnology Inc. (GTSM:3118) Still Undervalued? - Simply Wall St

PRINCETON, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that Andrew Saik has resigned as the Companys Chief Financial Officer (CFO) and a director of the board to pursue other professional opportunities, effective immediately. Mr. Saik joined PDS Biotech following the merger with Edge Therapeutics in March 2019, where he was the CFO. The board of directors has initiated a search to identify a successor.

The Companys board of directors has appointed Frank Bedu-Addo, Ph.D., the Companys President and Chief Executive Officer, as interim Principal Financial Officer and Janetta Trochimiuk, PDS Biotechs Controller as interim Principal Accounting Officer until a permanent replacement has been named. Ms. Trochimiuk is a seasoned finance professional with over 20 years of experience, serving as Controller and CFO of private and publicly listed companies. Ms. Trochimiuk holds a Bachelor of Business Administration from Bernard M. Baruch College and is a licensed CPA.

On behalf of our board of directors, we would like to thank Andrew for his service and contributions as we transitioned to a public company and successfully bolstered our balance sheet with the recent capital raise based on our promising Versamune platform technology. We wish him continued success in his future endeavors and look forward to announcing a permanent successor in the near term, said Dr. Frank Bedu-Addo, CEO of PDS Biotech.

About PDS BiotechnologyPDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotech is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechs pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.About PDS0101PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck, PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In partnership with the National Cancer Institute (NCI), PDS Biotech is also advancing a combination of PDS0101 and two clinical stage immunotherapies to a Phase 2 study in advanced HPV-associated cancers. A third phase 2 study is to be performed in advanced localized cervical cancer combining PDS0101 with the chemoradiotherapy, which is the standard of care.

Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely, believe, estimate, project, intend, and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation:; the Companys ability to protect its intellectual property rights; potential adverse reactions or changes to business relationships resulting from the resignation of the Companys Chief Financial Officer or the Companys ability to find a replacement Chief Financial Officerthe Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials; the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved; the timing of and the Companys ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Companys product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.Media & Investor Relations Contact:

Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Tram Bui / Alexander LoboThe Ruth GroupPhone: +1 (646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com / alobo@theruthgroup.com

Go here to read the rest:
PDS Biotechnology Announces Resignation of Andrew Saik as CFO - Associated Press

Biotechnology-Based Chemical Market Industry Forecast To 2024

Garner Insights has titled a new research report named as Biotechnology-Based Chemical Market 2020 to its consistently extending database. The report clarifies this through a series of channels which include data ranging from rudimentary data to an undeniable estimate. It consolidates all the fundamental factors that are foreseen to change inside the market. The information would thus be used to heighten an organizations standing in the worldwide market.

Based on the industrial chain, this report mainly elaborates the definition, types, applications and major players of Biotechnology-Based Chemical market in details. Deep analysis about Biotechnology-Based Chemical market status (2014-2019), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2024), regional industrial layout characteristics and policies has also be included.

Get a Sample Report @:https://www.garnerinsights.com/Global-Biotechnology-Based-Chemical-Market-Report-2020#request-sample

Major Manufacturer Detail:Queenslands world-class agriculture industry,Sarnia-Lambton Research,UK and Norway business funding agencies,Technology Strategy Board (TSB),Innovation Norway

The Important Type Coverage:Bio-pharma,Agri-biotech,Bio-informatics and,Bio-services

Segment by ApplicationsFood and beverages,Agriculture,Fuel,Energy,Animal feed

The Biotechnology-Based Chemical report consists of streamlined financial data obtained from various research sources to provide specific and trustworthy analysis. Evaluation of the key market trends with a positive impact on the market over the following couple of years, including an in-depth analysis of the market segmentation, comprising of sub-markets, on a regional and global basis. The report also provides a detailed outlook of the Biotechnology-Based Chemical market share along with strategic recommendations, on the basis of emerging segments.

Enquire Here For Discount Or Report @https://www.garnerinsights.com/Global-Biotechnology-Based-Chemical-Market-Report-2020#discount

Some Of The Major Geographies Included In This Study:

North America (U.S and Canada and Rest of North America)Europe (Germany, France, Italy and Rest of Europe)Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Some major points covered in this Biotechnology-Based Chemical Market report:

1. An overall outlook of the market that helps in picking up essential data.2. The market has been segmented on the basis of the product types, applications, end-users, as well as the industry verticals, in light of numerous factors. Considering the market segmentation, further analysis has been carried out in an effective manner. For better understanding and a thorough analysis of the market, the key segments have further been partitioned into sub-segments.3. In the next section, factors responsible for the growth of the market have been included. This data has been collected from the primary and secondary sources and has been approved by the industry specialists. It helps in understanding the key market segments and their future trends.4. The report also includes the study of the latest developments and the profiles of major industry players.5. The Biotechnology-Based Chemical market research report also presents an eight-year forecast on the basis of how the market is predicted to grow.

View Full Report @ https://garnerinsights.com/Global-Biotechnology-Based-Chemical-Market-Report-2020

About Us:Garner Insights is a Market Intelligence and consulting firm with an all-inclusive experience and vast knowledge of the market research industry.Our vast storage of research reports across various categories, gives you a complete view of the ever changing and developing trends and current topics worldwide. Our constant endeavor is to keep on improving our storage information by providing rich market reports and constantly improving them.

Contact Us:Mr. Kevin Thomas+1 513 549 5911 (US)+44 203 318 2846 (UK)Email: [emailprotected]

The rest is here:
Biotechnology-Based Chemical Market Key Drivers, Business Insights, Trends And Forecast To 2024 - Daily Science

Vir Biotechnology, a San Francisco-based biotechnology firm, said Wednesday that laboratory testing showed two of its antibody drugs appeared to neutralize the coronavirus that causes Covid-19 and that it would pursue testing them in people.

The company said that human tests of the drugs could begin in three to five months, putting it roughly in line with two other efforts to produce anti-coronavirus antibodies. Regeneron, based in Tarrytown, N.Y., has said that its antibodies could enter trials by early summer and that its treatment, if it proves effective, could be available for some uses in the fall. Eli Lilly, which is developing anti-SARS-CoV-2 antibodies with AbCellera, a Vancouver biotech, has said it hopes to begin human tests in four months.

Stopping this disease will take a combination of prevention and treatment approaches, Vir CEO George Scangos said in a statement. At Vir, we are fortunate that our existing antibody platform gave us a running start against COVID-19, and we have the internal and partnered capabilities to work on multiple approaches.

advertisement

Vir is working with the Cambridge, Mass., biotech firm Biogen, where Scangos was previously CEO, and Wuxi Biologics, a China-based manufacturing organization.

Antibodies are a part of the immune system that drug companies have learned to weaponize as treatments for diseases. An antibody drug against SARS-CoV-2 might either treat infection in very sick patients or prevent infection. It is one of many techniques researchers are attempting against Covid-19. For a rundown of approaches, see this story.

advertisement

Vir is taking a somewhat different approach from Regeneron. While Regeneron is going to choose two antibodies to use together, Vir has picked a single antibody. But Vir is modifying it in two different ways and testing the resulting two experimental drugs in parallel.

The first modification should make the antibodies last longer in the body, and is being done to both candidates. The second, in animal models, leads to long-term production of white blood cells that might lead to long-term immunity, as with a vaccine. If this proves effective, the antibody could be used to prevent infection.

Vir said it has also identified other antibodies that work differently, so that they might be combined with the two it is testing. And it is continuing to search for antibodies in the blood or patients who have survived SARS-CoV-2.

Read the rest here:
Vir Biotechnology reports early progress in antibody treatment for Covid-19 - STAT

Dublin, March 24, 2020 (GLOBE NEWSWIRE) -- The "Agricultural Biotechnology: Emerging Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The study scope includes key agricultural biotechnology tools (i.e., next-generation DNA sequencing, biochips, RNA interference, synthetic biology tools, and gene editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

The report analyzes these technologies and products to determine present and future market sizes, and to forecast growth from 2019 through 2024. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status and market driving forces.

The research provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS and microarray companies); major seed companies; biotech trait companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2018 and 2019.

96 agricultural and biotechnology companies are profiled in this report.

The report includes:

Market Insights

Global megatrends are driving the need for higher agricultural yields, creating strong tailwinds for innovative seed traits and biological pesticides and stimulants.

World population growth, coupled with rising incomes, lead to consumption of higher-quality foods, including meat. This, in turn, creates higher consumption of feed crops, including maize, soy, and wheat. At the same time, the total acreage of arable land available for producing crops is under pressure from a range of forces, including growing populations, urbanization, and global warming.

These global forces are creating leverage in the industry to increase productivity and crop yields. Biotechnology provides strategic tools for the agricultural industry to meet these market demands. This report examines the role of these technologies in agriculture and quantifies their market impact.

Reasons for Doing the Study

Agriculture is a fundamental and strategic component of a country. As a result, agricultural technologies provide competitive geographic advantage and are highly desirable. Biotechnologies address the pressing industry need for higher crop yields and other desirable traits. Agricultural biotechnology is a key and growing component of the global agriculture industry and is thus of interest to a wide audience.

This report seeks to provide a qualitative and quantitative description of the agricultural biotechnology industry so that emerging market opportunities can be identified and exploited by the reader. The report does this by examining the main product applications and markets, thereby helping companies to prioritize product opportunities and strategic opportunities. The report highlights key market and industry trends, as well as quantifying the main market segments, in order to help the reader better understand industry structure and changes occurring in the industry.

Rapid changes in technology-intensive fields such as DNA sequencing, gene editing, and synthetic biology are driving new products and applications in agriculture. These developments create unique market opportunities. This report analyzes these trends and their impact on future markets for agricultural products.

Based on these market and technology dynamics, it is especially timely to examine the agricultural biotechnology industry.

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 Technology Background

Chapter 5 Agricultural Biotechnology Applications

Chapter 6 DNA Read, Write and Edit Industries

Chapter 7 Acquisitions and Strategic Alliances

Chapter 8 Agricultural Biotechnology Markets

Chapter 9 Patents

Chapter 10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/hib70i

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Story continues

See more here:
Global Agricultural Biotechnology Markets, 2018-2024 - Discussion of the Opportunities in Biotechnology Tools, Genomic-Enabled Products and Biotech...

Board additions will enhance Companys ability to execute on key corporate initiatives

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc.. (Genprex or the Company) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments are designed to strengthen the Company as it executes on its key clinical programs, continues to build its pipeline, and evaluates future license or corporate partnership agreements. The new Board members include Brent Longnecker, Chief Executive Officer of Longnecker & Associates, Jose A. Moreno Toscano, Chief Executive Officer of LFB USA Inc, and William R. (Will) Wilson, Jr., Chairman, President and Chief Executive Officer of Wilson Land & Cattle Co.

This strengthening of the Board of Directors closely follows the Company receiving Fast Track Designation from the Food and Drug Administration (FDA) for its lead drug candidate, raising more than $26 million from institutional investors over the last few months, and licensing a new gene therapy drug candidate for diabetes from the University of Pittsburgh. Also, just yesterday, the Company announced that it strengthened its management team by adding two new senior executives, Catherine Vaczy as Executive Vice President and Chief Strategy Officer, and Michael Redman as Executive Vice President and Chief Operating Officer.

We are honored to have Brent, Jose and Will join our Board in what we believe is a transformational time for our Company, said Rodney Varner, Chief Executive Officer of Genprex. Their combined experience in regulatory compliance, business development, clinical trial management, and deal structuring will be invaluable as we continue to our develop gene therapy drug candidates and pursue partnerships for our drug candidates. The addition of these outstanding directors, together with our new senior executive hires and a significantly strengthened balance sheet, puts us in an excellent position to execute our plans.

Brent Longnecker has more than 30 years of experience in corporate governance, executive compensation, and risk management consulting for public, private, and non-profit organizations. Mr. Longnecker built one of the countrys leading privately-held executive compensation and corporate governance consultancies, serving both domestic and international markets. Mr. Longnecker has deep expertise in healthcare, energy, real estate, manufacturing, and financial companies, regularly consulting with boards of directors, CEOs, key executives, and advisors in many major industries. He is a prolific author on the subjects of executive compensation and corporate governance.

Jose A. Moreno Toscano brings to the Company over 20 years of experience in the pharmaceutical and biotechnology industries, building, developing and transforming organizations. Mr. Moreno Toscano has a successful track record of identifying and capitalizing on opportunities to drive exponential revenue growth and market expansion, revitalizing underperforming operations and establishing foundations for successful start-up operations. His experience includes strategic planning, corporate restructuring, business development, M&A, investor relations, and general management.

William R. Wilson, Jr. has more than 40 years of experience as an attorney, with legal experience spanning health care regulation, biotechnology, clinical trial management, nursing home licensing and regulation, physician accreditation, securities, corporate governance, and contractual matters. He previously served as Judge of the 250th District Court of Travis County, Texas, where he presided over civil litigation, as well as Assistant District Attorney for Dallas County, Texas.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases. The Companys lead product candidate, Oncoprex, is being evaluated as a treatment for non-small cell lung cancer (NSCLC). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso). For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding our possible commercial partnerships and regarding our financial resources. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of Oncoprex, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including our gene therapy in diabetes, advance into clinical trials; our ability to enter into strategic partnerships and the success of those partnerships; the timing and success of obtaining FDA approval of Oncoprex and our other potential product candidates; and the extent and duration of the current and future economic challenges we may face. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005120/en/

Go here to read the rest:
Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders - BioSpace

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from human embryonic stem cells has received notification from the U.S. Food and Drug Administration (FDA) that it has lifted the hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS). IMS001 was derived from the pluripotential cell line designated ESI-053 licensed from AgeX.

Since pluripotent stem cells are capable of differentiating into all human cell types potentially genetically modified in any manner, they open the door to a wide array of new therapies, stated Dr. Michael D. West, PhD, founder and CEO of AgeX. This collaboration with ImStem is consistent with our aim to make our clinical-grade pluripotent stem cell banks widely available for diverse therapeutic applications.

IMS001 is a formulation of cells derived from AgeX pluripotent stem cells induced to differentiate into mesenchymal cells (hES-MSC) and through a proprietary method using a trophoblast intermediate stage (hence also known as T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases. IMS001 is an investigational, allogeneic cell product to be administered intravenously to patients suffering from MS. ImStem believes this is the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA. ImStem plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.

The clinical-grade pluripotent stem cell lines from AgeX were the first published GMP-compatible lines ever created, said Xiaofang Wang, MD, PhD, Founder and Chief Technology Officer of ImStem. As such, they have been widely distributed in the scientific community and demonstrated to meet the needs of industry for relatively rapid product development.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About IMS001

IMS001 is an investigational, allogeneic, hES-MSC that has undergone IND-enabling, preclinical biodistribution, engraftment, tumorigenicity, toxicology, immunogenicity, and pharmacology studies. IMS001 has demonstrated preclinical immunomodulatory activities, which may lead to potential therapeutic benefits in a wide array of neurological, autoimmune, and rare orphan diseases with high unmet medical needs.

Previously published in-vitro data, in collaboration with scientists at the University of Connecticut (UConn) Health, have demonstrated potential advantages of hESC-MSCs in terms of their immunomodulatory effects, as well as the potential to stabilize the blood-brain-barrier (BBB). These mechanistic properties may lead to therapeutic benefits in diseases such as MS, potentially reducing relapses, disability progression, and inducing disease arrest.

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and Dr. Ren-He Xu, former director of UConn Stem Cell Institute, led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The companys mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem Biotechnology, Inc. is a privately held company headquartered in Farmington, CT. For more information, visit http://www.imstem.com.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

The rest is here:
AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for...

The 85 rating InvestorsObserver gives to Aytu Bioscience Inc (AYTU) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, AYTUs 85 overall rating means the stock scores better than 85 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aytu Bioscience Inc (AYTU) stock is down -16.08% while the S&P 500 has risen 3.65% as of 2:13 PM on Wednesday, Mar 25. AYTU has fallen -$0.32 from the previous closing price of $1.99 on volume of 21,555,025 shares. Over the past year the S&P 500 has fallen -10.00% while AYTU has risen 3.73%. AYTU lost -$1.88 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read this article:
Is Aytu Bioscience Inc (AYTU) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

The Global Agricultural Biotechnology For Transgenic Crops Market is expected to grow from USD 3,179.57 Million in 2018 to USD 9,904.57 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 17.62%.The latest report on Agricultural Biotechnology For Transgenic Crops Market added by Regal Intelligence, focus on market estimates and geographical spectrum of this industry. The report specifies information about Agricultural Biotechnology For Transgenic Crops industry regarding a thorough and detailed assessment of this business.

Further, the Agricultural Biotechnology For Transgenic Crops Market report details important challenges and factors that influence market growth. Further, a detailed comprehensive secondary research was done to collect information on the market segments and sub-segments. Further, primary research was performed to validate the assumptions and findings obtained from secondary research with industry professionals and experts.

Request Free Sample Report at https://www.regalintelligence.com/request-sample/24607

Competitive Landscape:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Agricultural Biotechnology For Transgenic Crops Market including are BASF SE, Bayer AG, Dow AgroSciences LLC, Monsanto Company, Pioneer Hi-Bred International, Inc., Agrilife, Land OLakes, Limagrain, Syngenta AG, and TAKII & CO.,LTD.. On the basis of Type, the Global Agricultural Biotechnology For Transgenic Crops Market is studied across Cisgenic, Multiple Trait Integration, Subgenic, and Transgenic.On the basis of Crop Type, the Global Agricultural Biotechnology For Transgenic Crops Market is studied across Cereals & Grains, Flowers, Fruits & Vegetables, Medicinal Herbs & Spices, and Oilseeds & Pulses.

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this Agricultural Biotechnology For Transgenic Crops Market report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers, and producers etc.

The primary sources from the demand side include Agricultural Biotechnology For Transgenic Crops industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, End-User (product buyers), and related key executives from various key companies and organizations operating in the global Agricultural Biotechnology For Transgenic Crops market.

Primary Types of the industry are

Primary Applications of the industry are

Ask For Table of [emailprotected] https://www.regalintelligence.com/request-toc/24607

This report is based on the synthesis, analysis, and interpretation of information collected on the Agricultural Biotechnology For Transgenic Crops market from various sources. Our analysts have analysed the information & data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the Agricultural Biotechnology For Transgenic Crops Industry.

The following market parameters were considered to estimate market value:

Market Overview

The report includes overviews market introduction, market drivers & influencing factors, restraints & challenges, and potential growth opportunities of Agricultural Biotechnology For Transgenic Crops market. The report consists of market evaluation tools such as Porters five forces, PESTLE Analysis, and value chain analysis.

Key Questions Addressed in the Report:

For more information and discount on this report, reach us at: https://www.regalintelligence.com/check-discount/24607

Thank you for Reading this article.

Read more:
Agricultural Biotechnology For Transgenic Crops Market Opportunities and Threats faced by the Key Vendors 2025 - Monroe Scoop

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $30.85 to be very precise. The Stock rose vividly during the last session to $37.4 after opening rate of $37 while the lowest price it went was recorded $30.22 before closing at $32.75.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.87% during the 52-week period from high price, and 164.80% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 562686 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 160.44%, having the revenues showcasing 166.91% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.13B, as it employees total of 217 workers.

During the last month, 2 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 20.80, with a change in the price was noted +16.66. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +115.45% for the period of last 100 days, recording 527,790 in trading volumes.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 29.02%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 7.73%. In the last 20 days, the companys Stochastic %K was 19.17% and its Stochastic %D was recorded 29.17%.

Lets take a glance in the erstwhile performances of Vir Biotechnology, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 160.44%. The shares increased approximately by 1.54% in the 7-day charts and went down by -34.84% in the period of the last 30 days. Common stock shares were driven by 166.91% during last recorded quarter.

Read more:
Gear up for the change! Vir Biotechnology, Inc. (VIR) has hit the volume of 562686 - The InvestChronicle

The "Epigenetic Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

The future of the epigenetic market looks promising with opportunities in the pharmaceutical and biotechnology industries. The global epigenetic market is expected to grow with a CAGR of 14% from 2019 to 2024. The major growth drivers for this market are declining sequencing costs and time, increasing research activities and availability of government funding, and rising cancer prevalence.

A report of more than 150 pages is developed to help in your business decisions. To learn the scope of, benefits, companies researched and other details of the epigenetic market, then read this report.

Some of the features of Global Epigenetic Market 2019-2024: Trends, Forecast, and Opportunity Analysis include:

This report answers the following 11 key questions:

Q.1 What are some of the most promising potential, high-growth opportunities for the global epigenetic market by product, application, technology, and region?

Q.2 Which segments will grow at a faster pace and why?

Q.3 Which regions will grow at a faster pace and why?

Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the epigenetic market?

Q.5 What are the business risks and threats to the epigenetic market?

Q.6 What are emerging trends in this epigenetic market and the reasons behind them?

Q.7 What are some changing demands of customers in the epigenetic market?

Q.8 What are the new developments in the epigenetic market? Which companies are leading these developments?

Q.9 Who are the major players in this epigenetic market? What strategic initiatives are being implemented by key players for business growth?

Q.10 What are some of the competitive products and processes in this epigenetic area and how big of a threat do they pose for loss of market share via material or product substitution?

Q.11 What M & A activities have taken place in the last 5 years in epigenetic market?

Key Topics Covered:

1. Executive Summary

2. Market Background and Classifications

2.1: Introduction, Background, and Classifications

2.2: Supply Chain

2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2013 to 2024

3.1: Macroeconomic Trends and Forecast

3.2: Global Epigenetic Market: Trends and Forecast

3.3: Global Epigenetic Market by Product Type

3.3.1: Enzymes

3.3.2: Kits

3.3.3: Reagents

3.3.4: Bioinformatics Tools

3.4: Global Epigenetic Market by Application

3.4.1: Oncology

3.4.2: Non Oncology

3.5: Global Epigenetic Market by End Use Industry

3.5.1: Pharmaceutical

3.5.2: Biotechnology

3.5.3: Others

3.6: Global Epigenetic Market by Technology

3.6.1: DNA Methylation

3.6.2: Histone Methylation

3.6.3: Histone Acetylation

3.6.4: Large Noncoding RNA

3.6.5: MicroRNA Modification

3.6.6: Chromatin structures

3.6.7: Others

4. Market Trends and Forecast Analysis by Region

4.1: Global Epigenetic Market by Region

4.2: North American Epigenetic Market

4.2.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.2.2: Market by Application: Oncology and Non Oncology

4.2.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.2.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.3: European Epigenetic Market

4.3.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.3.2: Market by Application: Oncology and Non Oncology

4.3.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.3.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.4: APAC Epigenetic Market

4.4.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.4.2: Market by Application: Oncology and Non Oncology

4.4.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.4.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.5: Row Epigenetic Market

4.5.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.5.2: Market by Application: Oncology and Non Oncology

4.5.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.5.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis

5.2: Market Share Analysis

5.3: Operational Integration

5.4: Geographical Reach

5.5: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis

6.1.1: Growth Opportunities for Global Epigenetic Market by Product Type

6.1.2: Growth Opportunities for Global Epigenetic Market by Application

6.1.3: Growth Opportunities for Global Market by End Use Industry

6.1.4: Growth Opportunities for Global Market by Technology

6.1.5: Growth Opportunities for Global Epigenetic Market by Region

6.2: Emerging Trends in Global Epigenetic Market

6.3: Strategic Analysis

6.3.1: New Product Development

6.3.2: Capacity Expansion of Global Epigenetic Market

6.3.3: Mergers, Acquisitions and Joint Ventures in the Global Market

7. Company Profiles of Leading Players

7.1: Illumina

7.2: Thermo Fisher Scientific

7.3: Merck Millipore

7.4: Abcam

7.5: Active Motif

7.6: Bio-Rad

See original here:
Global Epigenetic Market Expected to Grow with a CAGR of 14%, 2019-2024 - ResearchAndMarkets.com - Benzinga

Massachusetts is located in the northeastern region of the continental United States. Formally known as the Commonwealth of Massachusetts, the state has a long and storied history as one of America's original thirteen colonies. It was way back in the year 1620 that the first Pilgrims arrived in Plymouth aboard the Mayflower to begin their lives in the New World. Many years later, in 1782, Massachusetts became the sixth state to join the union. All these years later Massachusetts is known as a state which continues to play an integral role in a variety of integral aspects of modern American life especially in regards to the fields of politics, the economy, arts, and culture, as well as national identity.

With a slew of nicknames including the Old Colony State, Baked Bean State, and Puritan State, Massachusetts comprises a total area of 10,565 square miles. The state is currently home to a population of approximately 6,939,373 people and it's capital city, Boston, boosts the highest population rate of any urban center in New England. The leading industries in Massachusetts include biotechnology, maritime trade, engineering, information technology, finance, tourism, as well as higher education.

Biotechnology involves using technological methods in order to modify or alter the biological elements of an organism and/or living system(s). This is done as a means of creating brand new products or processes. Practical examples of biotechnology include the production of various hormones and antibiotics. A number of related scientific disciplines that often work hand in hand with biotechnology include such related fields as biomedical engineering and molecular biology.

Massachusetts' capital city, Boston, is the hub for the biotechnology industry in the state. The city, as well as the neighboring community of Cambridge, are both home to nearly a thousand biotech companies. One of the reasons for this is the large number of universities located in the area. Among the renowned institutes to have facilities in this part of Massachusetts is the Whitehead Institute for Biomedical Research and the Wyss Institute for Biologically Inspired Engineering. Local biotech companies in Massachusetts include ImmunoGen, Boston Scientific, and Vaxess Technologies.

Massachusetts' coastline on the Atlantic Ocean measures approximately 1,500 miles in length. This is the key reason why the state and many of the people who live there have had a long and illustrious relationship with the sea. For many years marine trade has played a vital part in Massachusetts' domestic economy. Local sports in the state have long enabled Americans to trade with communities in such far-flung parts of the world as China and the Caribbean.

For many years, fishing has been an important industry for those residents living on the Atlantic coast of the state. In the nineteenth century, for example, the New England area benefitted considerably from a boom in whaling activities. During this time whales were hunted for food as well as for the valuable oil they provided. Although saltwater fish stocks have been diminishing over the years due to factors such as overfishing and climate change, a large number of Massachusetts residents still make their living off the ocean and activities such as fishing and the harvesting of lobster and Atlantic horseshoe crabs. Among the valuable fish species to be found in the ocean waters off Massachusetts include haddock, monkfish, Atlantic cod, summer flounder, and black sea bass.

Engineering involves the use of scientific methods in order to design and create various structures such as roadways, buildings, tunnels, and bridges. One of Massachusetts' greatest advantages in terms of its engineering industry expertise is the sheer number of engineering colleges and educational facilities located within the state. An educated and highly specialized workforce is a key element in the state's collective success in the field of engineering. Some of these top-rated institutions in Massachusetts include the Massachusetts Institute of Technology (MIT), Franklin W. Olin College of Engineering, Wentworth Institute of Technology as well as a variety of universities including Harvard, Boston, and Tufts.

Commonly referred to as IT the field of information technology involves using computers in order to acquire, archive, and access data. Figures indicate that the northeastern state is home to about 1,708 organizations connected to information technology. Examples of IT companies operating in Massachusetts include Bloomer Health Tech and the Health Data Analytics Institute.

Financial companies make up an important part of the state's economy. As of 2015, it was estimated that approximately a dozen Fortune 500 companies are located in Massachusetts. In 2014 CNBC listed Massachusetts as the 25th best state in the U.S. for business. Financial companies operating in the state include names such as Fidelity Investments, Liberty Mutual Group, and the Massachusetts Mutual Life Insurance Company.

According to statistics from 2015, Massachusetts ranked sixth in terms of the most popular destinations for tourists traveling to the U.S. from other countries. Besides Boston, the state capital and largest city in the state, other communities popular with international visitors include Plymouth, where the Pilgrims landed, and Salem, site of the infamous witch trials. Other well known local attractions include a variety of historical, cultural, and recreational sites such as "Little Women" author Louisa May Alcott's Orchard House in Concord, the Boston Tea Party Ships and Museum, New Bedford Whaling Museum, and Lizzie Borden's house in Fall River.

The state is also home to numerous parks and natural attractions such as the Walden Pond State Reservation in Concord, Wellfleet Bay Wildlife Sanctuary, and Nickerson State Park.

Massachusetts has long been one of the top states in terms of being home to a myriad of educational institutes of higher learning. The state is home to Roxbury Latin School which has the distinction of being the oldest school in continuous operation since it was established in 1645. Massachusetts is also home to the oldest public elementary, high school, and boarding schools as well as the oldest college and women's' college in the nation. The number of higher learning institutions located in Massachusetts totals 121.

Schools of note in Massachusetts include not only Harvard and MIT but also Boston College, Northeastern University, Wellesley College, Amherst College, and the University of Massachusetts.

Read more:
What Are The Biggest Industries In Massachusetts? - World Atlas

The 31 rating InvestorsObserver gives to Vir Biotechnology Inc (VIR) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 12 percent of stocks in the Biotechnology industry, VIRs 31 overall rating means the stock scores better than 31 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 31 means the stock is more attractive than 31 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Vir Biotechnology Inc (VIR) stock is trading at $36.76 as of 12:45 PM on Monday, Mar 23, a drop of -$3.00, or -7.55% from the previous closing price of $39.76. The stock has traded between $36.15 and $39.94 so far today. Volume today is low. So far 218,746 shares have traded compared to average volume of 1,059,947 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original here:
Industry Breakdown: Where Does Vir Biotechnology Inc (VIR) Stock Fall in the Biotechnology Field? - InvestorsObserver

MIRAMAR, Fla. , March 19, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the companys proprietary and patented Ii-Key immune system activation technology. This guidance is designed to assist third party groups and government agencies in their evaluation of potential vaccines against this pandemic SARS-CoV-2 virus. The patented NuGenerexImmuno-Oncology (Formerly Antigen Express) Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation. Generex is working with our partners at EpiVax who have identified such protein fragments or epitopes to generate Ii-Key-SARS 2 peptide vaccines in collaboration with our peptide manufacturing partners. The peptides and Ii-Key are made from naturally occurring amino acids, ensuring an excellent safety profile for Ii-Key peptide vaccines.

Generex President & CEO Joseph Moscato said, Generex wants to let everyone know that we are ready and willing to partner on our coronavirus vaccine development program with government health agencies across the globe. Based on our discussions with numerous people throughout the U.S. government and international health agencies, it is clear that additional information is needed by the authorities about the potential to rapidly create a vaccine using our Ii-Key technology to fight the COVID-19 pandemic. Generex has long standing experience developing Ii-Key peptide vaccines for infectious diseases and cancer, so wehave developeda strategy to design, screen and identify vaccine peptides to any novel pathogenic virus to initiate human clinical trials in 3 to 5 months depending on regulatory agency requirements.We have vaccinated over 300 people with Ii-Key vaccines to demonstrate their safety and their ability to activate the immune response against peptide epitopes. As a public service to expedite the review of the Ii-Key vaccine technology by interested parties, we are providing a summary of safety on our Ii-Key development program from both published peer-reviewed literature as well as from our clinical investigator brochures on our website at Generex.com.

Mr. Moscato continued, We ask that governments, health ministries, and large pharmaceutical companies please take note of the potential for Ii-Key peptide vaccines to slow the spread of the SARS-CoV-2 virus. We are advancing the coronavirus project with our partners in China, and we are available to partner with other countries to develop and commercialize our Ii-Key-SARS-2 vaccine. To date we have been in touch with the VA, BARDA, and HHS in the United States, and we are in communication with the Canadian Ministry of Health, as well as with authorities in Greece, England, Saudi Arabia, Iceland, Indonesia, Philippines, Italy, and Romania for licensing our Ii-Key-SARS-2 peptide vaccines as well as new, patented immunotherapy technology that will provide those countries with co-ownership of the Intellectual Property in their territories. We have engaged Morris L. Reid of Mercury LLC (http://mercuryllc.com) to advise the company on international licensing strategy.

Defeating coronavirus requires a public/private partnership, stated Mr. Reid, Partner at Mercury. Government cannot do it alone and must collaborate with the private sector in order to bring the best innovation to the table.

Mr. Moscatoadded his thoughts on peptide vaccines, stating, We know one thing about vaccines and the immune response, and that is our immune system recognizes antigenic epitopes, which are made of amino acid peptides, and mounts a multicellular response to protect the body from invaders like viruses or cancer. Whether you use attenuated or killed viruses or recombinant proteins, peptides are and have been the primary pathway to create vaccines. Peptide vaccines, especially when linked with the Ii-Key, are proven to generate an immune response, and we have demonstrated the safety of various Ii-Key peptide vaccines in animal models and human clinical trials. Over the years, Generex has developed a proven process to generate rapid peptide vaccines using the latest computational algorithms to select the best peptides to create an immune response, and we can link these peptide epitopes to the Ii-key for a very powerful solution that is cost effective and easy to manufacture on a large scale. Every country in the world needs our Ii-key technology in their national health arsenal not only for this coronavirus, but also to respond to future SARS virus mutations and other potential pandemic viruses that have been on the rise the last 20 years.

Story continues

For further information from government or corporate inquiries please email:covid-19@nugenerexio.com

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

NuGenerex Immuno-Oncology (formerly Antigen Express), a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD-4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) is being spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Mercks Keytruda) for the treatment of triple negative breast cancer.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato

646-599-6222

Todd Falls

Tel: 1-800-391-6755 Extension 222 Email: investor@generex.com

Excerpt from:
Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the SARS-CoV-2...